Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, SEPT. 03, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON SEPTEMBER 1, 2026, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 11,535 SHARES OF ITS COMMON STOCK TO SIXTY-SIX NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

PRAXIS PRECISION MEDICINES, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, AUG. 04, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON AUGUST 3, 2026, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 7,318 SHARES OF ITS COMMON STOCK TO TWENTY-NINE NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

BOSTON, JULY 30, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 AND PROVIDE A CORPORATE UPDATE, BEFORE THE FINANCIAL MARKETS OPEN ON THURSDAY, AUGUST 6, 2026.

PRAXIS PRECISION MEDICINES TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON THURSDAY, AUGUST 6, 2026

COLLABORATION AIMS TO QUICKLY ENABLE ULIXACALTAMIDE TO BE DELIVERED VIA ACTIVE TRANSDERMAL ROUTE POTENTIAL TO EXPAND THE ADDRESSABLE MARKET FOR ULIXACALTAMIDE BEYOND THE INITIAL PATIENT POPULATION AND TO ENABLE ADDITIONAL LIFE-CYCLE MANAGEMENT OPPORTUNITIES PRAXIS TO MAKE EQUITY INVESTMENT IN REMAGINE LABS, ACCELERATING THE COMPANIES' COLLABORATION BOSTON, MASS. AND AUSTIN, TEXAS, JULY 07, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES , INC. (NASDAQ: PRAX), A FULLY INTEGRATED CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, AND REMAGINE LABS, INC., A DEVELOPER OF ELECTRONICALLY CONTROLLED TRANSDERMAL DRUG DELIVERY SYSTEMS, TODAY ANNOUNCED A RESEARCH COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AN IONTOPHORETIC TRANSDERMAL PATCH FOR THE DELIVERY OF ULIXACALTAMIDE, PRAXIS'S HIGHLY SELECTIVE T-TYPE CALCIUM CHANNEL INHIBITOR IN DEVELOPMENT FOR ESSENTIAL TREMOR (ET).

PRAXIS PRECISION MEDICINES AND REMAGINE LABS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP TRANSDERMAL ULIXACALTAMIDE FOR ESSENTIAL TREMOR

BOSTON, JULY 02, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON JULY 1, 2026, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 951 SHARES OF ITS COMMON STOCK TO FIVE NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

FDA SETS UPDATED PDUFA DATE OF DECEMBER 27, 2026 BOSTON, JUNE 29, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES , INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) NOTIFIED PRAXIS THAT IT HAS EXTENDED BY THREE MONTHS THE REVIEW PERIOD FOR ITS NEW DRUG APPLICATION (NDA) FOR RELUTRIGINE FOR THE TREATMENT OF SCN2A AND SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEES), SETTING AN UPDATED PDUFA TARGET ACTION DATE FROM SEPTEMBER 27, 2026 TODECEMBER 27, 2026. THE EXTENSION FOLLOWS PRAXIS'S SUBMISSION OF ADDITIONAL SENSITIVITY ANALYSES OF EXISTING CLINICAL DATA, WHICH THE FDA HAS DEEMED A "MAJOR AMENDMENT," ALLOWING ADDITIONAL TIME FOR THE FDA TO REVIEW.

PRAXIS PRECISION MEDICINES ANNOUNCES EXTENSION PERIOD FOR RELUTRIGINE FOR TREATMENT OF SCN2A AND SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES

THE BREAKTHROUGH THERAPY DESIGNATION (BTD) WAS GRANTED BASED ON THE POSITIVE RESULTS FROM THE EMBRAVE PART A TRIAL OF ELSUNERSEN ELSUNERSEN DEMONSTRATED A 77% SHAM-ADJUSTED REDUCTION IN MONTHLY SEIZURES (P=0.015), WITH BENEFIT SUSTAINED IN THE OPEN-LABEL EXTENSION FOR UP TO ONE YEAR THE PIVOTAL EMBRAVE3 STUDY IS ENROLLING UNDER A STREAMLINED, SINGLE-ARM REGISTRATIONAL PATHWAY ALIGNED WITH THE FDA ELSUNERSEN NOW HOLDS BREAKTHROUGH THERAPY, ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FROM THE FDA, AND ORPHAN DRUG AND PRIME DESIGNATIONS FROM THE EMA BOSTON, JUNE 22, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES , INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BTD FOR ELSUNERSEN (PRAX-222), AN ANTISENSE OLIGONUCLEOTIDE (ASO) FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (SCN2A-DEE) CAUSED BY GAIN OF FUNCTION (GOF) VARIANTS IN SCN2A. OUR THIRD BREAKTHROUGH THERAPY DESIGNATION FOR THE LATE-STAGE PIPELINE IS A DEFINING MILESTONE FOR PRAXIS, WITH IMMEDIATE IMPLICATIONS FOR THE ELSUNERSEN PROGRAM AND FOR OUR SOLIDUS ASO PLATFORM.

PRAXIS PRECISION MEDICINES RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR ELSUNERSEN FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY CAUSED BY GAIN OF FUNCTION VARIANTS

BOSTON, JUNE 04, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED IT WILL BE PRESENTING A CORPORATE OVERVIEW AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE 2026 TAKING PLACE IN MIAMI, FL AT THE LOEWS MIAMI BEACH HOTEL ON MONDAY, JUNE 8, 2026 AT 8:00AM ET.

PRAXIS PRECISION MEDICINES TO PARTICIPATE IN GOLDMANS SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

BOSTON, JUNE 02, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 2,754 SHARES OF ITS COMMON STOCK TO THIRTEEN NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

POWER1 STUDY IN HIGHLY REFRACTORY PATIENTS WITH FOCAL ONSET SEIZURES DID NOT MEET ITS PRIMARY SUCCESS MEASURE SECONDARY MEASURE, THE 50% RESPONSE RATE, WAS MET AND SEIZURE REDUCTION DURING THE SECOND HALF OF THE STUDY ON HIGHER DOSE (30 MG) WAS MORE PRONOUNCED VORMATRIGINE WAS GENERALLY WELL-TOLERATED; ADVERSE EVENT-RELATED DISCONTINUATIONS WERE LESS THAN 10% APPROXIMATELY 90% OF PATIENTS FROM THE VORMATRIGINE ARM TRANSITIONED TO AND REMAIN IN THE OPEN LABEL EXTENSION (OLE) STUDY PRAXIS IS PAUSING ENROLLMENT IN THE POWER2 STUDY TO REASSESS THE VORMATRIGINE PROGRAM AND DETERMINE POTENTIAL MODIFICATIONS BOSTON, JUNE 01, 2026 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES , INC. (NASDAQ: PRAX), A FULLY INTEGRATED, LEADING CENTRAL NERVOUS SYSTEM (CNS) PRECISION NEUROSCIENCE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED RESULTS FROM THE PHASE 2/3 POWER1 STUDY EVALUATING VORMATRIGINE IN PATIENTS WITH FOCAL ONSET SEIZURES (FOS). WHILE THE RESULTS FOR POWER1 WERE NOT WHAT WE HOPED FOR, WE ARE ENCOURAGED BY THE SIGNAL WE SAW ON THE HIGHER DOSE ARM, THE LOW DISCONTINUATION RATE AND SOLID SAFETY PROFILE, SAID MARCIO SOUZA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF PRAXIS.

Praxis Precision Medicines, Inc.

PRAX

Price

Financial Reports

No items found.

Press Releases

Praxis Precision Medicines, Inc.

PRAX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PRAX